FBIO.P Stock Overview
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Fortress Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.90 |
| 52 Week High | US$18.91 |
| 52 Week Low | US$6.40 |
| Beta | 1.53 |
| 1 Month Change | -17.31% |
| 3 Month Change | 6.93% |
| 1 Year Change | -24.08% |
| 3 Year Change | -44.75% |
| 5 Year Change | -30.14% |
| Change since IPO | -42.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| FBIO.P | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.4% | 1.5% | 1.2% |
| 1Y | -24.1% | 1.1% | 24.7% |
Return vs Industry: FBIO.P underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: FBIO.P underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| FBIO.P volatility | |
|---|---|
| FBIO.P Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FBIO.P's share price has been volatile over the past 3 months.
Volatility Over Time: FBIO.P's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 186 | Lindsay Rosenwald | www.fortressbiotech.com |
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea.
Fortress Biotech, Inc. Fundamentals Summary
| FBIO.P fundamental statistics | |
|---|---|
| Market cap | US$34.81m |
| Earnings (TTM) | -US$68.67m |
| Revenue (TTM) | US$84.51m |
0.4x
P/S Ratio-0.5x
P/E RatioIs FBIO.P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FBIO.P income statement (TTM) | |
|---|---|
| Revenue | US$84.51m |
| Cost of Revenue | US$132.73m |
| Gross Profit | -US$48.22m |
| Other Expenses | US$20.45m |
| Earnings | -US$68.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.57 |
| Gross Margin | -57.05% |
| Net Profit Margin | -81.25% |
| Debt/Equity Ratio | 4,271.4% |
How did FBIO.P perform over the long term?
See historical performance and comparison